共 122 条
[1]
Weichselbaum RR(2011)Oligometastases revisited Nat Rev Clin Oncol 8 378-382
[2]
Hellman S(2013)Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy Ann Oncol 24 2881-2886
[3]
Schweizer MT(2014)Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer Prostate 74 297-305
[4]
Zhou XC(2013)Stereotactic body radiotherapy for oligometastases Lancet Oncol 14 e28-e37
[5]
Wang H(2015)Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature Eur Urol 67 852-863
[6]
Yang T(2009)Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer Cancer 115 2388-2399
[7]
Shaukat F(2015)Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: A single-center experience Clin Genitourin Cancer 13 e279-e284
[8]
Partin AW(2009)New response criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
[9]
Eisenberg MA(1995)Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1341-1346
[10]
Antonarakis ES(2013)Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy Clin Genitourin Cancer 11 27-32